Apple was initiated with a buy rating at Lazard. $540 price target. Company still has strong competitive advantages, Lazard Capital Markets said.
Bona Film Group was downgraded to sell at TheStreet Ratings.
Coleman Cable was upgraded to buy at TheStreet Ratings.
Carmike Cinemas was upgraded to buy at TheStreet Ratings.
VAALCO Energy was downgraded to hold at TheStreet Ratings.
Embraer was upgraded to buy at TheStreet Ratings.
Meadowbrook Insurance Group was upgraded to buy at TheStreet Ratings.
Microsoft was downgraded from buy to neutral BofA/Merrill. $33 price target. Windows 8 lacks momentum, Bank of America/Merrill Lynch said.
Panera Bread was upgraded to buy at Goldman. $215 price target. Company also placed on the Conviction List. Company can continue to grow units and same-store sales, Goldman Sachs said.
OMNOVA Solutions was downgraded to hold at TheStreet Ratings.
Ocean Shore Holding was downgraded to hold at TheStreet Ratings.
Pharmacyclics was downgraded to hold at TheStreet Ratings.
Peoples Federal Bancshares was upgraded to buy at TheStreet Ratings.
Duke Energy was downgraded from buy to hold at Argus. Valuation call, as the stock has outperformed its peers year-to-date, Argus Research said.
Brinker was upgraded to buy at Goldman. $44 price target. Company could see better domestic traffic growth, Goldman Sachs said.
PremierWest Bancorp was upgraded to hold at TheStreet Ratings.
Sykes Enterprises was upgraded to buy at TheStreet Ratings.
United Bancorp was upgraded to buy at TheStreet Ratings.
China Xiniya Fashion was upgraded to hold at TheStreet Ratings.
Yelp was initiated as hold at TheStreet Ratings.
Aruba Networks was downgraded to neutral at UBS. Given multiple expansion and stock performance, the current valuation is fair, said UBS.
Brown & Brown was upgraded from sell to neutral at Goldman. Company can continue to generate solid organic growth, Goldman Sachs said. $33 price target.
Ulta Beauty was upgraded to buy at Jefferies. $100 price target. Stock is attractive, following a 20% pullback, Jefferies said.
Avista was downgraded to neutral at UBS based on valuation. Recent share price appreciation reflects recent successes in the rate case arena, said UBS.
Centurylink was upgraded from neutral to overweight at JP Morgan. $38 price target. Had a positive meeting with management and feel better about the long-term business outlook, JP Morgan said.
Finisar was upgraded from neutral to buy at Lazard. $17 price target. Risk/reward is attractive at current levels, Lazard Capital Markets said.
STOCK COMMENTS/EPS CHANGES
Acuity Brands price target was raised to $83 as the North American market is expected to show improving business trends in the second half of the year, said UBS.
Bed Bath & Beyond price target and earnings estimates were increased through 2014 at UBS. Q4 earnings will be in-line, but the online strategy will be the key to future success, said UBS. Price target goes to $64
Domino's Pizza was removed from the conviction buy list, according to Goldman Sachs. Valuation call, based on a $60 price target.
LinkedIn estimates, target were boosted at Morgan Stanley. Shares are now seen reaching $210, according to Morgan Stanley. Estimates also upped, given higher marketing solutions growth. Overweight rating.
Nokia estimates, target were cut at Canaccord. Shares are now seen reaching $3.50, according to Canaccord Genuity. Estimates also reduced, as the company is likely losing market share to Samsung. Hold rating.
Monsanto price target and earnings estimates through 2014 were increased at Citi. Soybeans should drive growth starting in 2014 and the accelerated buyback is also a catalyst, said Citigroup. Price target goes to $122.
Monsanto estimates, target raised at Piper as the company is carrying a lot of momentum into the planting season. Overweight rating.
New York Community Bancorp estimates were reduced at Citi through 2014 to reflect a soft quarter. Lower pre-payments and margins are expected and the anticipated accretive merger is unlikely to happen, said Citigroup.
Thermo Fisher price target increased to $87 at UBS. Industry commentary has been positive, top line momentum remains intact and productivity and capital deployment will benefit the company, said UBS.
Valent price target and estimates were reduced given the introduction of a generic version of Zovirax Ointment, said UBS. Price target goes to $81.
>To submit a news tip, email: email@example.com.